Uploaded October 2026 | Updated November 2026, 7 hours ago
Plasma proteomics offers great promise for biomarker discovery, due to the accessibility and diagnostic relevance of blood plasma. Recent advances in instrumentation, particularly the Orbitrap Astral mass spectrometer, now enable unprecedented depth, with over 1,000 proteins routinely quantified directly in neat plasma, without the need for depletion or fractionation. This development is transforming the landscape of high-throughput biomarker research.
In addition, nanoparticle- or precipitation-based enrichment workflows can further expand proteome coverage, offering orthogonal strategies to access low-abundance proteins and diverse functional subsets. However, all these approaches remain highly susceptible to pre-analytical variation. Factors such as sample collection, handling, and storage can introduce significant bias, confounding both discovery and interpretation. Therefore, rigorous standardization and quality control are critical to ensure reproducibility and biological relevance.
We will illustrate both the challenges and opportunities of plasma biomarker discovery using two example cohorts: one from bariatric surgery and one from patients with Giant Cell Arteritis. Together, these case studies highlight how deep plasma proteomics can uncover disease-relevant signals, while also underscoring the need for methodological care to ensure robust biological insights.
Learning Objectives:
- Understand the analytical challenges of plasma biomarker discovery for cohort studies
- Learn about technology advancements to improve depth and throughput for plasma biomarker discovery
- How to apply best practices for standardization and quality control in plasma proteomics
- What workflow developments can be leveraged to uncover disease relevant signals in sample cohorts
Speaker:
Sebastian Virreira Winter, PhD - Chief Technology Officer, Managing Director & Co-Founder, ions.bio
Speaker Biography:
I studied Molecular Biomedicine at the Univ of Bonn and spent 15 months at the Whitehead Institute for Biomedical Research in Cambridge, MA as a visiting research scholar to perform my diploma thesis research in the field of biochemistry and infection research. I did my Ph.D. at the Max Planck Institute for Infection Biology in Berlin, Germany. My research was focused on the role of reactive oxygen species and redox reactions in innate immune signaling. Furthermore, I studied required host factors for alpha hemolysin from Staphylococcus aureus using a CRISPR/Cas9 screen. I then joined the laboratory of MS-based proteomics pioneer Matthias Mann at the Max Planck Institute of Biochemistry in Germany, as a postdoc. There, I developed a novel isobaric tag that allow highly precise and accurate proteome quantifications. Additionally, I co-developed the BoxCar scan mode and MaxQuant.Live, a software tool to control Orbitrap mass spectrometers and implement custom scan modes and target ten thousand of peptides per MS run. Following my contributions to technological advances in MS-based proteomics, I focused my research on clinical proteomics, particularly on biomarker discovery in Parkinson’s disease. I developed a scalable and sensitive workflow for biomarker discovery in urine and also analyzed two cohorts of cerebrospinal fluid samples from Parkinson’s disease patients. I was involved in developing a targeted assay for pRab10 in clinical specimen. In July 2024, I co-founded ions.bio. Our vision is to improve the use of MS-based proteomics for the analysis of clinical samples to accelerate biomarker discovery and validation to improve patient care. To achieve this, we integrate the entire value-chain of biomarker discovery and validation, starting from setting up our own biobank, deep molecular phenotyping of clinical specimen using our advanced LC-MS/MS platform as well as developing sophisticated data analytics workflows to deliver actionable results to our clients.
Plasma proteomics offers great promise for biomarker discovery, due to the accessibility and diagnostic relevance of blood plasma. Recent advances in instrumentation, particularly the Orbitrap Astral mass spectrometer, now enable unprecedented depth, with over 1,000 proteins routinely quantified directly in neat plasma, without the need for depletion or fractionation. This development is transforming the landscape of high-throughput biomarker research.
In addition, nanoparticle- or precipitation-based enrichment workflows can further expand proteome coverage, offering orthogonal strategies to access low-abundance proteins and diverse functional subsets. However, all these approaches remain highly susceptible to pre-analytical variation. Factors such as sample collection, handling, and storage can introduce significant bias, confounding both discovery and interpretation. Therefore, rigorous standardization and quality control are critical to ensure reproducibility and biological relevance.
We will illustrate both the challenges and opportunities of plasma biomarker discovery using two example cohorts: one from bariatric surgery and one from patients with Giant Cell Arteritis. Together, these case studies highlight how deep plasma proteomics can uncover disease-relevant signals, while also underscoring the need for methodological care to ensure robust biological insights.
Learning Objectives:
- Understand the analytical challenges of plasma biomarker discovery for cohort studies
- Learn about technology advancements to improve depth and throughput for plasma biomarker discovery
- How to apply best practices for standardization and quality control in plasma proteomics
- What workflow developments can be leveraged to uncover disease relevant signals in sample cohorts
Speaker:
Sebastian Virreira Winter, PhD - Chief Technology Officer, Managing Director & Co-Founder, ions.bio
Speaker Biography:
I studied Molecular Biomedicine at the Univ of Bonn and spent 15 months at the Whitehead Institute for Biomedical Research in Cambridge, MA as a visiting research scholar to perform my diploma thesis research in the field of biochemistry and infection research. I did my Ph.D. at the Max Planck Institute for Infection Biology in Berlin, Germany. My research was focused on the role of reactive oxygen species and redox reactions in innate immune signaling. Furthermore, I studied required host factors for alpha hemolysin from Staphylococcus aureus using a CRISPR/Cas9 screen. I then joined the laboratory of MS-based proteomics pioneer Matthias Mann at the Max Planck Institute of Biochemistry in Germany, as a postdoc. There, I developed a novel isobaric tag that allow highly precise and accurate proteome quantifications. Additionally, I co-developed the BoxCar scan mode and MaxQuant.Live, a software tool to control Orbitrap mass spectrometers and implement custom scan modes and target ten thousand of peptides per MS run. Following my contributions to technological advances in MS-based proteomics, I focused my research on clinical proteomics, particularly on biomarker discovery in Parkinson’s disease. I developed a scalable and sensitive workflow for biomarker discovery in urine and also analyzed two cohorts of cerebrospinal fluid samples from Parkinson’s disease patients. I was involved in developing a targeted assay for pRab10 in clinical specimen. In July 2024, I co-founded ions.bio. Our vision is to improve the use of MS-based proteomics for the analysis of clinical samples to accelerate biomarker discovery and validation to improve patient care. To achieve this, we integrate the entire value-chain of biomarker discovery and validation, starting from setting up our own biobank, deep molecular phenotyping of clinical specimen using our advanced LC-MS/MS platform as well as developing sophisticated data analytics workflows to deliver actionable results to our clients.










